Markets
Impact BioMedical Inc. (IBO)
IBOAMEXBiotechnology: Pharmaceutical Preparations
$5.14
+0.3602 (+7.54%) today
Closed, Nov 13, 3:54 PM ET
+7.54% 1D
- Market cap
- $44.58m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.43 to $10.47
- Average volume
- –
- Previous close
- $4.78
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $7,000 | $7,000 | $3,000 | $21.0k |
| Gross profit | -$415.0k | $7,000 | $2,000 | $14.0k |
| Operating income | -$1.17m | -$2.29m | -$701.0k | -$649.0k |
| Net income | $5.25m | -$2.29m | -$698.0k | -$647.0k |
Last four quarters: revenue $38.0k, margin 4244.7%, free cash flow –
News
7 latest- Impact Biomedical Files Form F-4 For Proposed Zoar Business Combination RTTNews · Sep 16, 2026
- Impact Biomedical Issues Correction On Merger Exchange Ratio As Reverse Stock Split Takes Effect RTTNews · Sep 15, 2026
- Impact BioMedical Announces Reverse Stock Split To Advance Merger With Zoar Ltd. RTTNews · Sep 14, 2026
- Impact BioMedical Shares Surge Over 115% On Amended Merger And Share Exchange Agreement RTTNews · Mar 5, 2026
- Dr Ashleys To Acquire Impact BioMedical In Reverse Merger, IBO Shares Surge RTTNews · Jun 23, 2025
- Dr Ashleys Limited and Impact BioMedical Announce Strategic Merger to Enhance Pharmaceutical InnovationsQuiver Quantitative · Jun 23, 2025
- Insider Sale: 10% owner at $IBO Sells 53,280 SharesQuiver Quantitative · Mar 24, 2025
The company
Impact Biomedical Inc. discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.